© 2002

Targets for Cancer Chemotherapy

Transcription Factors and Other Nuclear Proteins

  • Nicholas B. La Thangue
  • Lasantha R. Bandara

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Marina Schorpp-Kistner, Peter Herrlich, Peter Angel
    Pages 29-52
  3. Eun Joo Chung, Paolo Bonvini, Ho Jung Oh, Len Neckers, Jane Trepel
    Pages 71-100
  4. Stuart Thomson, Louis C. Mahadevan
    Pages 101-122
  5. Manfred Jung
    Pages 123-144
  6. R. Nagaraja Rao, Bharvin K. R. Patel
    Pages 145-178
  7. Antonio Chiloeches, Richard Marais
    Pages 179-205
  8. Andrea Klotzbücher, Michael H. G. Kubbutat
    Pages 207-234
  9. Anastasia Gabriel, Alan Ashworth
    Pages 235-247
  10. David Pim, Miranda Thomas, Lawrence Banks
    Pages 249-273
  11. Mathieu H. M. Noteborn
    Pages 275-287
  12. Debabrata Banerjee, Joseph R. Bertino
    Pages 289-298
  13. Heidi M. Sowter, Adrian L. Harris
    Pages 299-313
  14. H. M. Oosterkamp, R. Bernards
    Pages 315-339
  15. Back Matter
    Pages 341-352

About this book


Recent scientific discoveries concerning therapeutically relevant protein targets that contribute to cancer pathology have opened new possibilities in the search for effective cancer treatments. In Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins, a panel of leading basic researchers, pharmaceutical scientists, and clinical oncologists provide, in an easy-to-understand format, a detailed account of these latest research developments and spell out their implications for cancer drug discovery and clinical application. The authors identify and illuminate selected transcription factor oncoproteins and tumor suppressors, together with nuclear proteins that are central to the phenotype of the tumor cell and including recently elucidated enzymes involved with chromatin control. The emphasis is on new targets and approaches to cancer treatment derived from the cancer cell cycle, gene and chromatin control targets, and angiogenesis. Among the targets considered are E2F, Myc oncoproteins, hypoxic signaling pathways, Mdm2 and ARF, the AP-1 family of transcription factors, histone deacetylase, histone acetyl transferase, apoptin, and nuclear ß-catenin signaling.
Up-to-date and insightful, Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins shows clearly how our new understanding of critical molecular targets in cancer cells can be applied to cancer drug discovery to provide new drug discovery platforms both for future development and for new target-based medicines for cancer patients.


BRCA angiogenesis positron emission tomography regulation tumorigenesis

Editors and affiliations

  • Nicholas B. La Thangue
    • 1
    • 2
  • Lasantha R. Bandara
    • 3
  1. 1.Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life SciencesUniversity of GlasgowGlasgowScotland
  2. 2.Prolifix Ltd.Abingdon, OxonUK
  3. 3.Oxford Glycosciences Ltd.Abingdon, OxonUK

Bibliographic information

  • Book Title Targets for Cancer Chemotherapy
  • Book Subtitle Transcription Factors and Other Nuclear Proteins
  • Editors Nicholas B. La Thangue
    Lasantha R. Bandara
  • Series Title Cancer Drug Discovery and Development
  • DOI
  • Copyright Information Springer Science+Business Media New York 2002
  • Publisher Name Humana Press, Totowa, NJ
  • eBook Packages Springer Book Archive
  • Hardcover ISBN 978-0-89603-938-4
  • Softcover ISBN 978-1-61737-263-6
  • eBook ISBN 978-1-59259-153-4
  • Series ISSN 2196-9906
  • Series E-ISSN 2196-9914
  • Edition Number 1
  • Number of Pages XII, 352
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Topics Oncology
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology


'This book will be of interest to drug development professionals and oncology researchers. Specific chapters make good reviews for clinicians interested in emerging therapies and may also be useful for students." - Today's Life Science

"The book is included in the successful series of publications "Cancer Drug Discovery and Development" form Humana Press. It will be of interest both to clinicians and to laboratory cancer researchers, as well as to people who are interested in recent achievements in molecular oncology, which gives new hope for better treatment of caner patients." - Neoplasma